Regorafenib in Treating Patients with Metastatic Medullary and Differentiated Radioiodine Refractory Thyroid Cancer

Status: Temporarily Closed to Accrual and Intervention

Description

This phase II trial studies how well regorafenib works in treating patients with medullary thyroid cancer that has spread to other places in the body (metastatic), and differentiated radioiodine thyroid cancer that does not respond to treatment (refractory). Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Eligibility Criteria

Inclusion Criteria

  • Subjects must be able to understand and be willing to sign the written informed consent form; a signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure
  • Eastern Cooperative Oncology Group performance status of: 1
  • Histologically or cytologically confirmed diagnosis of metastatic medullary thyroid cancer (MTC COHORT IS NOW CLOSED) or histologically or cytologically confirmed diagnosis of RAI refractory differentiated thyroid cancer for which no curative treatment option exists
  • Documented disease progression as defined by RECIST within 6 months prior to study registration for patients with MTC and within 12 months prior to study registration for patients with RAI refractory DTC
  • Must have at least 1 site of measurable disease by RECIST criteria, by version 1.1
  • Archival tissue block or unstained slides (from primary or metastatic site) must be available, otherwise fresh tissue biopsy sample will be collected for patients with accessible tumors
  • Any number of prior chemotherapies and targeted therapies are allowed
  • Patients must have received at least one prior line of targeted therapy
  • Total bilirubin =< 1.5 x the upper limits of normal (ULN) within 3 weeks prior to study registration
  • Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) within 3 weeks prior to study registration
  • Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) within 3 weeks prior to study registration
  • Serum creatinine =< 1.5 x the ULN within 3 weeks prior to study registration
  • International normalized ratio (INR)/ partial thromboplastin time (PTT) =< 1.5 x ULN within 3 weeks prior to study registration; subjects who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists ; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care
  • Platelet count > 100000 /mm^3 within 3 weeks prior to study registration; blood transfusion to meet the inclusion criteria will not be allowed
  • Hemoglobin (Hb) > 9 g/dL within 3 weeks prior to study registration; blood transfusion to meet the inclusion criteria will not be allowed
  • Absolute neutrophil count (ANC) 1500/mm^3 within 3 weeks prior to study registration; blood transfusion to meet the inclusion criteria will not be allowed
  • Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to study registration; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test; the definition of adequate contraception will be based on the judgment of the investigator
  • Subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 2 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate
  • Subject must be able to swallow and retain oral medication

Exclusion Criteria

  • Prior treatment with regorafenib
  • Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study
  • Uncontrolled hypertension (systolic pressure > 140 mm Hg or diastolic pressure > 90 mm Hg (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.0) on repeated measurement) despite optimal medical management
  • Active or clinically significant cardiac disease including: * Congestive heart failure – New York Heart Association (NYHA) > Class II * Active coronary artery disease * Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin * Unstable angina (anginal symptoms at rest), new-onset angina within 3 months before randomization, or myocardial infarction within 6 months before randomization
  • Evidence or history of bleeding diathesis or coagulopathy
  • Any hemorrhage or bleeding event >= NCI CTCAE v4.0 grade 3 within 4 weeks prior to study registration
  • Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study registration
  • Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before registration are allowed; all cancer treatments must be completed at least 3 years prior to study registration
  • Patients with pheochromocytoma
  • Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
  • Ongoing infection > grade 2 NCI-CTCAE v4.0
  • Symptomatic metastatic brain or meningeal tumors
  • Presence of a non-healing wound, or non-healing ulcer, (that is not tumor related) or bone fracture
  • Major surgical procedure or significant traumatic injury within 28 days before start of study registration
  • Other investigational treatment during or within 30 days before starting study registration
  • Use of any approved tyrosine kinase inhibitors within 2 weeks or 6 half-lives of the agent, whichever is shorter, prior to study registration
  • Prior radiation within 14 days before start of study registration
  • Renal failure requiring hemo-or peritoneal dialysis
  • Dehydration grade >= 1 NCI-CTCAE v4.0
  • Patients with seizure disorder requiring medication
  • Persistent proteinuria >= grade 3 NCI-CTCAE v4.0
  • Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
  • Pleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)
  • History of organ allograft (including corneal transplant)
  • Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
  • Any malabsorption condition
  • Women who are pregnant or breast-feeding
  • Any condition which, in the investigator’s opinion, makes the subject unsuitable for trial participation
  • Substance abuse, medical, psychological or social conditions that may interfere with the subject’s participation in the study or evaluation of the study results
  • Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib, other agents being investigated in combination with regorafenib)
  • Prior use of regorafenib
  • Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks prior to study registration
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
  • Therapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids; however, prophylactic anticoagulation as described below is allowed: * Low dose warfarin (1 mg orally, once daily) with prothrombin time (PT)-INR =< 1.5 x ULN is permitted; infrequent bleeding or elevations in PT-INR have been reported in some subjects taking warfarin while on regorafenib therapy; therefore, subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes * Low dose aspirin (=< 100 mg daily) * Prophylactic doses of heparin
  • Use of any herbal remedy (e.g. St. John’s wort [hypericum perforatum])

Locations & Contacts

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. To evaluate proportion progression-free at 10 months in patients with medullary thyroid cancer (MTC).

II. Response rate by Response Evaluation Criteria in Solid Cancers (RECIST) criteria. (For radioiodine [RAI] refractory thyroid cancer)

SECONDARY OBJECTIVES:

I. To evaluate the safety and tolerability.

II. To evaluate radiographic response per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 (medullary TC only).

III. To assess quality of life.

IV. To evaluate candidate biomarkers and associate with response (calcitonin and carcinoembryonic antigen [CEA] in MTC, thyroglobulin in RAI refractory differentiated thyroid cancer [DTC]).

OUTLINE: This is a dose escalation trial of regorafenib.

Patients receive regorafenib orally (PO) once daily (QD) on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years.

Trial Phase & Type

Trial Phase

Phase II

Trial Type

Treatment

Lead Organization

Lead Organization
Dana-Farber Harvard Cancer Center

Principal Investigator
Jochen Hanns-Martin Lorch

Trial IDs

Primary ID 15-350
Secondary IDs NCI-2016-00333
Clinicaltrials.gov ID NCT02657551